Tocilizumab versus anakinra in COVID-19: results from propensity score matching

Tocilizumab versus anakinra in COVID-19: results from propensity score matching

BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the o...

Full description

Bibliographic Details
Main Authors: Robin Arcani, Florian Correard, Pierre Suchon, Gilles Kaplanski, Rodolphe Jean, Raphael Cauchois, Marine Leprince, Vincent Arcani, Julie Seguier, Benjamin De Sainte Marie, Baptiste Andre, Marie Koubi, Pascal Rossi, Stéphane Gayet, Nirvina Gobin, Victoria Garrido, Joris Weiland, Elisabeth Jouve, Anne-Laure Couderc, Patrick Villani, Aurélie Daumas
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
anakinra
tocilizumab
anti-interleukin drugs
COVID-19
mortality
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185716/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185716/full

Similar Items